The short version of synaptogenesis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Phalen's maneuver. Performed by fully flexing the wrist, then holding this position and awaiting symptoms. A positive test results in paresthesia in the median nerve distribution within sixty seconds. Tinel's sign is performed by lightly tapping the median nerve just proximal to flexor retinaculum to elicit paresthesia. Durkan's test, carpal compression test, or applying firm pressure to the palm over the nerve for up to 30 seconds to elicit paresthesia. The hand elevation test, performed by lifting both hands above the head. Paresthesia in the median nerve distribution within 2 minutes is considered positive. Diminished threshold sensibility (the ability to distinguish different amounts of pressure) can be measured using Semmes-Weinstein monofilament testing. This test establishes impaired or loss of sensation. Electrodiagnostic testing including electromyography, and nerve conduction studies can objectively measure and verify median neuropathy. Ultrasound can image and measure the cross-sectional diameter of the median nerve, which has some correlation with CTS. The role of ultrasound in diagnosis—just as with electrodiagnostic testing—is a matter of debate. Data suggests that electrodiagnostic testing cannot detect the presence of CTS in 16% to 34% of people who have the condition. The role of confirmatory electrodiagnostic testing is controversial. The goal of electrodiagnostic testing is to compare the speed of conduction in the median nerve with conduction in other nerves supplying the hand.
=== Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry (since 1985) === 2021 Veronica M. Bierbaum 2020 Kimberly A. Prather 2019 Jennifer S. Brodbelt 2018 Carol Vivien Robinson 2017 Vicki H. Wysocki 2015 Hilkka I. Kenttämaa 2010 Catherine E. Costello 2008 Catherine C. Fenselau 1990 Marjorie G. Horning
== Further reading == Rees, Jonathan. Refrigeration Nation: A History of Ice, Appliances, and Enterprise in America (Johns Hopkins University Press; 2013) 256 pages Refrigerators and food preservation in foreign countries. United States Bureau of Statistics, Department of State. 1890.
Sources: en.wikipedia.org
== Etymology == The term "oxytocin" derives from the Greek ὀξυτόκιον (oxytokion), based on ὀξύς (oxús), meaning "sharp" or "swift", and τόκος (tókos), meaning "childbirth". The adjective form is "oxytocic", which refers to medicines that stimulate uterine contractions, to speed up the process of childbirth. Colloquially, it has been referred to as the "cuddle hormone," "hug hormone," or "love hormone" because of extensive evidence of its involvement in mating and social behavior. It is involved in mating behavior in animals as low as C. elegans.
== Management == Treatment requires identifying and removing any causative medications and correcting any underlying electrolyte abnormalities. While TdP often self-resolves, cardioversion may be indicated if patients become hemodynamically unstable, as evidenced by signs such as hypotension, altered mental status, chest pain, or heart failure. Intravenous magnesium sulfate has been proven to be highly effective for both the treatment and prevention of TdP. Managing patients with TdP is dependent on the patient's stability. Vital signs, level of consciousness, and current symptoms are used to assess stability. Patients who are stable should be managed by removing the underlying cause and correcting electrolyte abnormalities, especially hypokalemia. An EKG should be obtained, a cardiac monitor should be attached, IV access should be established, supplemental oxygen should be given, and blood samples should be sent for appropriate studies. Patients should be continually re-evaluated for signs of deterioration until the TdP resolves. In addition to correcting the electrolyte abnormalities, magnesium given intravenously has also been shown to be helpful. Magnesium sulfate given as a 2 g IV bolus mixed with D5W can be given over a period of 15 minutes in patients without cardiac arrest Atrial pacing or administering isoproterenol can normalize the heart rate. Unstable patients exhibit signs of chest pain, hypotension, elevated heart rate, and/or heart failure. Patients who develop cardiac arrest will be pulseless and unconscious.
== Physiology and industrial uses == Rhizopus oryzae is involved in steroid transformations and it produces 4-desmethyl steroids which has been useful in the fermentation industry. The carbon sources does influence the ratio of polar and neutral lipids. The mycelium found in R. oryzae contains lipids and the highest lipid content occurs when grown on fructose. The highest unsaturated fatty acid content is observed at 30 °C and lowest at 15 °C. Proteolytic properties have been observed well under the conditions of pH 7 at 35 °C. Pyridozine and thiamine prefer proteinase production. R. oryzae can degrade aflatoxin A1 to isomeric hydroxy compounds and aflatoxin G1 to fluorescent metabolite aflatoxin A1. There are various factors that influence the production of dextro-lactic acids, fumaric acid, and metabolism of R. oryzae. For examples, in 40 °C there is more favorable growth for glucose consumption, however this influenced production of d-lactic acid production negatively. Glucose concentration of 15% is needed for optimal production of d-lactic acid. Fumaric acid production was suppressed in media containing more than 6 grams of NH4NO3 per liter and is favorable to d-lactic acid production. Rhizopus oryzae is considered GRAS by the FDA and thus recognized as safe to use industrially as it can consume a range of carbon sources. During fermentation. R. oryzae produce amylase, lipase, and protease activity to increase nutrient's ability to use many compounds as an energy and carbon source.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.